Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 11/20 | 0.49 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.48 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996807 | 0.85 | MAPT (0.50) | HPGDHTTS1PR4S1PR2S1PR5 | |
| SCHEMBL13809597 | 0.79 | S1PR4 (0.52) | HPGDHTTS1PR4S1PR2S1PR5 | |
| SCHEMBL19242999 | 0.79 | MAPT (0.54) | HPGDS1PR4S1PR2S1PR3MAPT | |
| SCHEMBL266467 | 0.78 | PTPN1 (0.47) | HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL805123 | 0.77 | HSD17B2 (0.52) | HPGDHTTS1PR4S1PR2S1PR5 | |
| SCHEMBL799579 | 0.77 | HPGD (0.49) | HPGDHTTS1PR4S1PR2S1PR5 | |
| SCHEMBL14363094 | 0.76 | L3MBTL1 (0.50) | MAPTNPSR1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL1616485 | 0.76 | ALDH1A1 (0.53) | HPGDHTTS1PR4MAPTNPSR1 | |
| SCHEMBL13078669 | 0.74 | SLC9A1 (0.63) | S1PR4S1PR2S1PR5S1PR3MAPT | |
| SCHEMBL4697667 | 0.73 | HPGD (0.65) | HPGDHTTS1PR4S1PR2S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-9428522-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2016-08-30 | — | — | US | disclosed |
| US-9382204-B2 | Inhibitors targeting the DNA-binding domain of human STAT3 for treatment of metastatic cancers | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382204-B2 | Inhibitors targeting the DNA-binding domain of human STAT3 for treatment of metastatic cancers | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150094353-A1 | Inhibitors Targeting the DNA-Binding Domain of Human STAT3 for Treatment of Metastatic Cancers | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-04-02 | — | — | US | disclosed |
| US-20150094353-A1 | Inhibitors Targeting the DNA-Binding Domain of Human STAT3 for Treatment of Metastatic Cancers | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-04-02 | — | — | US | disclosed |
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2014-11-20 | — | — | US | disclosed |
| US-8822472-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120010259-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094353-A1 | Inhibitors Targeting the DNA-Binding Domain of Human STAT3 for Treatment of Metastatic Cancers | STAT3, STAT6, STAT1 | HPGD 3796/4885HTT 3875/4885S1PR4 3621/4885 |
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA2 | HPGD 951/4885HTT 2856/4885S1PR4 674/4885 |
| US-20120010259-A1 | Methods of Treating an Overweight or Obese Subject | METAP2, METAP1, ACER2 | HPGD 2251/4885HTT 2450/4885S1PR4 284/4885 |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRM5 | HPGD 1280/4885HTT 2916/4885S1PR4 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.